
Alterity Therapeutics Limited American Depositary Shares
ATHE
ATHE: Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.
moreShow ATHE Financials
Recent trades of ATHE by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ATHE's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Acyl hydrazone derivative compounds for treating disease Mar. 14, 2023
-
Patent Title: Method of treating immunoglobulin light chain amyloidosis Jun. 14, 2022
-
Patent Title: Compounds for and methods of treating diseases Oct. 26, 2021
-
Patent Title: Imidazo [1,5-a]pyridine compounds and their use Mar. 09, 2021
Federal grants, loans, and purchases
Followers on ATHE's company Twitter account
Number of mentions of ATHE in WallStreetBets Daily Discussion
Recent insights relating to ATHE
Recent picks made for ATHE stock on CNBC
ETFs with the largest estimated holdings in ATHE
Flights by private jets registered to ATHE